Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with mRNA ...

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...

Announced days before a trial, the deal settles a longstanding dispute and avoids what one analyst called a “worst-case ...

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

Arbutus and Genevant's complaint claimed that Moderna's mRNA-based Spikevax shot used lipid nanoparticle (LNP) delivery ...

Investors who closely watch the healthcare sector are keeping an eye on Moderna (NASDAQ:MRNA) as its shares are up 12% over ...

In a conversation with Pharmaceutical Executive Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law ...

Barclays 28th Annual Global Healthcare Conference March 10, 2026 9:30 AM EDTCompany ParticipantsLavina Talukdar - Senior VP & ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

If you are wondering whether Moderna's share price really reflects what the business is worth today, you are not alone. That is exactly what this article will unpack. The stock recently closed at ...

The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center ...